For TREATMENT-NAÏVE patients with nAMD

START STRONG

STAY STRONG

NOW WITH EXTENDED DOSING beyond Q81

NEW in nAMD!

After 3 monthly EYLEA® loading doses and one injection at Week 16, treatment can continue with proactive Q8 dosing or proactive treat-and-extend (T&E) dosing beyond Q81,a

Vision gains

Strong and sustained vision gains with proactive Q8 dosing (VIEW), or proactive T&E dosing beyond Q8 (ALTAIR)2,3

Read more

Proactive T&E dosing

With proactive T&E dosing beyond Q8 in Year 1a, 57% of patients had a next intended injection interval of ≥12 weeks in the ALTAIR study at the end of Year 13,b

Read more

Year 1 posology

New proactive T&E dosing beyond Q8 gives you the flexibility to extend dosing or alternatively you can continue to use proactive Q8 dosing, according to your patients’ needs1,a

Read more

VEGF suppression

EYLEA delivers long-lasting anti-VEGF activity in the eye, for up to twice as long as ranibizumab4

Read more

a The recommended dose for EYLEA is 2 mg aflibercept, equivalent to 50 microliters. EYLEA treatment is initiated with one injection per month for three consecutive doses. The treatment interval is then extended to 8 weeks. Based on the physician’s judgment of visual and/or anatomic outcomes, the treatment interval may be maintained at 8 weeks or further extended using a T&E dosing regimen, where injection intervals are increased in 2- or 4-weekly increments to maintain stable visual and/ or anatomic outcomes. The schedule of monitoring visits may be more frequent than the injection visits. Treatment intervals greater than 16 weeks between injections have not been studied.
Beyond 52 weeks the treatment interval may be extended, such as with a T&E dosing regimen, where the treatment intervals are gradually increased to maintain stable visual and/or anatomic outcomes; however, there are insufficient data to conclude the length of time of these intervals. For further dosing information please refer to the EYLEA Summary of Product Characteristics (SmPC).
b The ‘next intended injection interval’ was defined as the time between the last injection and the next scheduled injection at the final study visit at Week 52.

nAMD, neovascular age-related macular degeneration; Q8, 2 mg every-8-weeks; RCT, randomized controlled trial; T&E, treat-and-extend; VEGF, vascular endothelial growth factor.

References

  1. EYLEA® (aflibercept solution for injection) Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG; July 2018.
  2. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
  3. Okada AA, Takahashi K, et al. Use of Intravitreal Aflibercept Treat-and-Extend Dosing for Wet Age-Related Macular Degeneration: 52-Week ALTAIR Results. Poster presented at the American Academy of Ophthalmology (AAO) Congress New Orleans, LA, November 11–14, 2017. Available from: https://aao.scientificposters.com/epsWelcome.cfm?CFID=6335346&CFTOKEN=47c8b80ef1e0478c-3912E1EF-E986-D0BE-7EE9563148B676EF.
  4. Fauser S, Muether PS. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol 2016;100:1494–1498.